Drug Abuse News and Research

RSS

Millennium Laboratories supports CLIA certification for Florida clinical laboratories

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, today announced the company’s support for a recent decision by the Florida Pain Management Clinic Standards of Practice Joint Committee to amend draft regulatory language related to the certification of clinical laboratories providing services to pain physicians operating in the state.

2 Feb 2010

Positive results from Phosphagenics' TPM Phase 1B clinical study for transdermal delivery of oxycodone

Phosphagenics Limited today announced positive results from a Phase 1B clinical study using the Company’s patented TPM™ (Targeted Penetration Matrix) for the transdermal delivery of oxycodone. The results of the successful trial demonstrate that daily application of a TPM™ patch delivers therapeutic levels of oxycodone into the blood stream in a reproducible, consistent and sustained manner.

2 Feb 2010

New mental health coverage rules promise to end some discrimination

Reuters: Employer-provided group health plans must offer the same level of coverage for mental illness and drug abuse treatment as for other ailments, according to federal regulations issued on Friday.

31 Jan 2010

NIDA supports Omeros' Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers.

28 Jan 2010

Blocking CRF may prevent excessive alcohol consumption

A team of scientists from The Scripps Research Institute has found that a specific stress hormone, the corticotropin-releasing factor (CRF), is key to the development and maintenance of alcohol dependence in animal models.

28 Jan 2010

Study examines how opioid overdose differs by prescribed dose for chronic pain conditions

More and more Americans with chronic pain not caused by cancer are taking medically prescribed opioids like Oxycontin (oxycodone) and Vicodin (hydrocodone). The January 19 Annals of Internal Medicine features the first study to explore the risk of overdose in patients prescribed opioids for chronic noncancer pain in general health care.

19 Jan 2010

NIDA researchers receive prestigious PECASE awards

Two researchers from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, have been awarded the White House Office of National Science and Technology Council's Presidential Award for Early Career Scientists and Engineers (PECASE). NIDA grantees Dr. Bruce J. Hinds, III and Dr. Gonzalo E. Torres will receive their awards today during a ceremony at the Commerce Building in Washington, DC.

18 Jan 2010

Obama's latest dilemma: Confronting the AIDS pandemic

Confronting the ongoing AIDS pandemic for his upcoming first national HIV/AIDS Strategy is President Obama's newest dilemma, say former New York City Mayor Ed Koch, former White House Drug Policy spokesman Robert Weiner, and Dartmouth College Coalition for Progress president Jordan Osserman.

18 Jan 2010

Pisgah Labs files its eighth patent application for technology to prevent prescription drug abuse

According to the Office of National Drug Control Policy, prescription drug abuse is more prevalent than abuse of cocaine, heroin and methamphetamine. In fact, in the past year, prescription drug abuse ranked second only to marijuana use. In the face of this growing problem, Pisgah Labs, Inc. has just filed its eighth patent application on a technology that promises to curb prescription drug abuse.

13 Jan 2010

Positive results from KemPharm's KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm’s proprietary Ligand Activated Therapy (LAT) prodrug approach.

12 Jan 2010

NOTA questions FDA's attempted regulation of on-site tests

The National On-site Testing Associates, Inc. (NOTA) has been revived in response to an attempt by the federal Food and Drug Administration (FDA) to regulate on-site, or point of collection, oral fluids drug and alcohol tests used by many small employers for non-medical purposes. NOTA is an association of manufacturers, users, and distributors of on-site drugs of abuse tests. These tests are sold throughout the world for use in workplace, sports, school, insurance, and criminal justice settings and numerous other non-medical applications. These tests are safe, accurate, cost effective, and easy to use.

9 Jan 2010

Researchers identify key epigenetic mechanism that helps explain cocaine's addictiveness

Researchers have identified a key epigenetic mechanism in the brain that helps explain cocaine's addictiveness, according to research funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

8 Jan 2010

Ongoing state budget cuts continue to impact health care services in California

Ongoing state budget cuts continue to negatively impact health care services in California. The latest round of budget cuts has eliminated additional health-services programs, including a prominent program for incarcerated women who suffer from drug and alcohol abuse.

8 Jan 2010

Rx Locker device to secure prescription medications

Due to the rising statistics about teens and prescription drug abuse, Dr. Drew Pinsky, host of Celebrity Rehab and Loveline, recently debuted the Rx Locker, a device designed to secure prescription medications within the home to restrict unauthorized access and prevent abuse.

7 Jan 2010

Apoteket and Medco Health Solutions develop centralized prescription safety program

Apoteket, Sweden's largest pharmacy chain, and Medco Health Solutions, Inc. today announced that it has developed one of the first national centralized drug utilization review (DUR) programs outside of the United States to improve prescription safety by reducing adverse drug events and thereby reducing the risk of costly hospitalizations.

7 Jan 2010

Physicians fail to provide pain treatment for fear of prescription drug abuse

Millions of Americans with significant or chronic pain associated with their medical problems are being under-treated as physicians increasingly fail to provide comprehensive pain treatment - either due to inadequate training, personal biases or fear of prescription drug abuse.

5 Jan 2010